Veru - VERU Stock Forecast, Price & News

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Veru Trading Down 4.6 %

Shares of VERU opened at $11.50 on Wednesday. Veru has a 12 month low of $4.34 and a 12 month high of $18.40. The stock's 50 day moving average is $13.34 and its two-hundred day moving average is $9.85. The firm has a market cap of $920.85 million, a P/E ratio of -33.82 and a beta of -0.40.

Veru (NASDAQ:VERU - Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $13.03 million during the quarter, compared to analysts' expectations of $15.18 million. Veru had a negative net margin of 45.56% and a negative return on equity of 18.64%. During the same quarter last year, the business earned ($0.04) EPS. Equities research analysts forecast that Veru will post -0.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VERU. HC Wainwright upped their price objective on Veru from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 12th. Jefferies Financial Group upped their price objective on Veru from $33.00 to $55.00 in a research note on Friday, May 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Veru in a research note on Friday, May 13th. Brookline Capital Acquisition raised their target price on Veru from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, May 18th. Finally, TheStreet raised Veru from a "d+" rating to a "c" rating in a report on Friday, April 29th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Veru has a consensus rating of "Buy" and a consensus price target of $35.40.